🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Orexo AB (publ) (STO:ORX)
Sweden flag Sweden · Delayed Price · Currency is SEK
0.9500
-0.0560 (-5.57%)
Nov 19, 2026, 2:22 PM CET
← View all transcripts

BioStock Life Science Summit 2026

Nov 5, 2026

Summary

AmorphOX’s stability and manufacturing capabilities underpin late-stage programs and partnering efforts. Near-term catalysts include IZIPRY’s FDA decision and OX640 pivotal results early next year, supported by rights-issue proceeds and partner funding.

Nikolaj Sørensen
President and CEO, Orexo

I am going to present Orexo today. It is really, at the moment, a story of two tales. We have one tale, which is our stock price and where we are at the capital market. We just announced a rights issue, and the reaction on the stock market has not been friendly to the stock, to say it mildly. The other part is our research and development and where we actually deliver. During the last few weeks, we have come up with several good news in our pipeline, and I will come back to that shortly. Here we are. What are we looking at? Orexo, we are working on a platform we call AmorphOX. It is quite scalable, something we have tested in both emergencies, small molecules, but also up to large molecules like vaccines, and so that is proteins, and show that it works for nasal delivery.

It also works to keep the very sensitive large molecules stable under quite harsh conditions, like 40 or 50 degrees Celsius, and quite an extended period of time. Otherwise, molecules that needs to be kept frozen to survive. We have taken products to the markets. We have just filed our fifth product in the U.S., so we are expecting approval early next year. We have done that before in markets all over the world, so in that way, we have taken products from the early idea all the way to the market.

One of the areas that I think Orexo is really good at is something that most companies ignore, in the early stages at least, and that is the CMC, creating manufacturing opportunities. We have met some of the harshest or toughest manufacturing opportunities or challenges. We are meeting a 99.999% reliability requirement on our emergency products in the U.S.

We have a platform that has been validated, talked about that, both in emergency products, but also in large molecules, and we have shown increasingly getting more and more, in particular in vivo data, but we also have quite a lot of human data from the products that are in late stage. We have a pipeline right now in late stage that are targeting markets that are north of $4 billion. One of them is just in filing. The other one could be filed as early as 2028, and I will come back to that shortly. Just looking at where we are, there are a lot of quite large milestones and the catalyst coming up in the company quite relatively shortly, and that means within the next six months.

Those who have been following Orexo for a while, we have moved a little the opposite direction of what many other companies aspire to. We had a product in the U.S. market. We sold that end of last year. I think the U.S. market is great, but it is ruthless, it is tough. We have been in legal litigations for at least 10 of the 12 years I have been with the company. It has cost us more than SEK 500 million, so I can tell you, without legal litigations, we would not have had to raise any money. During the last year, we have been streamlining the operations. We have closed down our U.S. business. That has been relatively costly, both of laying off people, exiting contracts in U.S., and also getting out of some of the rebates commitments that we have to pay us relating to old sales.

We are now where we want to be from an organizational and company perspective. We have transformed. We now cleaned out most of the legacy business and the expenses. We have a platform that we have proven into work, both in humans and also on the CMC front. We are then advancing. Part of it is advancing our own programs, so I will come back to those a little later.

An d part of that is finding partners who wants to work with our platform and see opportunities to use this amorphous powder that can keep very sensitive molecules stable for an extended period of time. We have done it before. We have done partnerships. We have taken products to the market quite a few times. So, it is for Orexo, it is not a new story. We are not starting from a blank sheet of paper. We are coming in with quite a heritage.

As I said before, we just announced rights issues. That has been tough on the company, and particularly on our shareholders. I am one of the larger ones, so of course, I am also hit by that. What we will use the proceeds from the rights issue is to invest into our late-stage pipeline. That is where most of the money will go, but of course, also to facilitate our early-stage programs. With the money coming in right now, it is subscribed and guaranteed up to 70%, so we will get SEK 175 million before emission or transaction cost. What are we working at? We call it AmorphOX. It is a platform that we have shown. It is an amorphous powder. Amorphous is very, very high energy state. It is very hard to keep stable.

It is a little the holy grail, because if you can put it into amorphous state, the formulation, you can control when you want to release it in a way, and it releases very, very quickly. We think this is very good for nasal. It could be worked in inhalation, but we can also do reconstitution if you want to keep something stable for a period of time and then be able to inject it when you mix it up with water, and then you can inject it. Because we have shown in these large molecules that we can keep molecules that otherwise needs to be frozen at minus 70 degrees, we have kept stable at 50 degrees Celsius after a month. So, that is just showing the strengths of the platform. We are working with partners to show this.

We have done a lot of early-stage partnerships, and we, of course, aspire to move this into real partnerships where the company will get milestones and real revenues. So, our focus is on three areas. We have what we call Explore, and that is basically testing the borderlines of this amorphous powder. We are working in particular with peptides. We are starting with semaglutide, partly because it is an excellent model substance. You both have tablets to compare with and a lot of data. We have some quite promising data in both nasal and oral. We are working with a partner in semaglutide to explore, and that is one of those I hope will turn into a real partnership as we go along. We also work in vaccines. In vaccines, we have partnership with a Swedish company. We are expanding that into academia, both in Sweden and the U.S.

We have an application in the U.S. at the moment together with a quite well-known U.S. institution to see if we can do some research together with them on AmorphOX combined with vaccines. Where we're putting most of the money is in our development platform. That's where we have IZIPRY, we just filed with the FDA. We have a PDUFA date on March 29 next year. We have our OX640. We have finished the first upscale manufacturing. We manufactured 12,000 units during the summer. We're just about to get the last quality control. You say, "Why do you talk about that? That's not that important." Just look at where the complete response letters are coming in Sweden, at least for the last 12 months. Most companies do not fail in clinical trials. Most companies fail in the CMC end.

This one, we have to deliver on 99.999% reliability. That is not many other products that have to deliver on that. By releasing that, we've shown that we can manufacture under those conditions. We have our OX390 program. It's a new emergency product for treating adulterated opioid overdose. I'll come back to that a little later, but we have received a grant from BARDA, U.S. authority, of up to $54 million to do that. Finally, we're working with partnering our amorphous platform with other companies. I will speed up a little on some of these opportunities due to time. In the semaglutide, we showed last year, we did an in vivo test on nasal comparing to RYBELSUS. We had up to seven times higher bioavailability than the RYBELSUS tablet. We've continued to work on this, and we've then done an oral tablet.

We reached the same comparable level as the most advanced tablet on the market today. The interesting part is, so why is that important? We did that on our first trial after just a few months of development. The development to take to the Wegovy tablet has taken years and millions and millions of Danish kroners to invest for Novo Nordisk, and we did it on a first trial. We are now expanding. We did that together with a partner who supported us with both some API, reference tablets, and also with a lot of scientific input. We're now expanding that partnership also to look into other delivery formats, and we have quite hopes that this could work out to be something that we can build a business on in the future.

We are now basically in the stage where we're taking this development further and together with a partner. As I said before, stability, of course, this is also stable, and we have seen no degradation in room temperature after several months, or actually it was 40 degrees. Then we have our other development programs. We have the ones that are more advanced. IZIPRY, I talked about. IZIPRY is an overdose treatment for opioids in the U.S. What is really interesting with opioid overdose in the U.S. is that people are dying from synthetic opioids. There's been a lot of resistance to higher dose opioid overdose treatments because of the risk of withdrawal symptoms. But today, the standard treatment is to use two or three of the low-dose products that are available immediately. Why is that important for Orexo?

It is because that suddenly put a price tag on the treatment for one patient that is possible to come in with a branded product. OX640 is for anaphylaxis, where we have the first nasal product on the market in the U.S. It is doing okay. It did a good second quarter, but it still has to build up the market, and the same goes for Europe. We see that the price recognition, particularly in Europe, for this product is good. When you look at why we think we have a great product, it is because our bioavailability profile is much better, in particular under nasal rhinitis conditions. This means when you have an allergic reaction, we have an extended, much faster uptake, and we also have an extended uptake in the product. 390 is the one that we got from BARDA.

When you look at televisions and you see these zombie drugs in the U.S., people think that people are using opioids. They are combining opioids with an animal tranquilizer. It is called xylazine. Why do you do that? I do not know, but they do that, and it is expanding rapidly. The growth from 2024 to 2025 is 215%. It is now in some states, for example, in Michigan, this is found in most illicit drugs that you find.

We have a nearly fully funded product program by the U.S. authority, BARDA, with $54 million. We have all the commercial rights to the product when it is done. I would like to just jump to the last slide here. Why do we think this is? What are the catalysts coming in with the company? We have OX640. We will have pivotal trial results early next year. IZIPRY approval early next year.

We are working to expand our partnerships, both on looking for partners for these two programs to take them to the market, but we are also working on our other products to find partners. We do have on semaglutide, for example, an industry partner that works with us in a scientific way, but of course, we hope to make that a more solid partnership moving forward. Then we work a lot in vaccines, in particular with academic institutions, but also with a Swedish and U.S. company. With that, I will open up for Q&As. Thank you.

Speaker 2

Thank you.

Moderator

Yep, we have a question right at the back.

Speaker 4

I could scream. Thank you. I am a bit confused. You are proposing to solve the opioid problems by selling opioids? Is not there a sort of very severe ethical question surrounding these products? I did not get what you said.

Nikolaj Sørensen
President and CEO, Orexo

What we are coming out with is an antagonist to opioids, is naloxone. We don't have an opioid.

Speaker 4

Yes, I'm aware of that.

Nikolaj Sørensen
President and CEO, Orexo

We don't have an opioid. This is an overdose treatment.

Speaker 4

But you're still targeting the population.

Nikolaj Sørensen
President and CEO, Orexo

Yeah, but it is people who are overdosing. You have to reverse the overdose, and we are providing an emergency product so people are basically on the edge of dying, or actually clinically they are dead.

Speaker 4

Sorry to interrupt, but it was, you know.

Nikolaj Sørensen
President and CEO, Orexo

We do not have an opioid that we are treating. ZUBSOLV that we had before was a replacement therapy, but we sold that. We do not have that.

Speaker 4

That is great. Thank you for the clarification.

Moderator

Any other questions?

Speaker 5

What was on the slide you had to skip? Because I really appreciate—

Nikolaj Sørensen
President and CEO, Orexo

No, it's—

Speaker 5

—people speed up, so I will ask you that.

Nikolaj Sørensen
President and CEO, Orexo

It was around the financing, and we are having a rights issue right now. As I said, it is guaranteed and subscribed. I am one of those who also going to subscribe to this and have signed up for that, including a lockup. So, that is ongoing at the moment. It has been ruthless, I think, on the stock market to the reaction to this, unfortunately. But it secures the funding for the company for quite a while forward. What is good with the pharma companies, most of our expenses are not humans and buildings. It is the projects, doing clinical trials, manufacturing products. So, we can kind of extend our runway a little as we want to, depending on how fast we are proceeding with the projects. But we also have an earnout for ZUBSOLV that we have.

We expect to receive more than SEK 50 million in Q1 from ZUBSOLV that will come into the company. We have royalties coming from ZUBSOLV in Europe. We have royalties coming from two other products, even though it is quite small and decreasing, but there are still a few millions coming into the company. We have partnerships that are already today with BARDA, who is financing most of the project for our OX390 projects. We have other partners that we expect to come in and fund part, or already now fund part of the development. So, we are kind of risk minimizing, but of course, doing a rights issue in the current environment is not something that is well received on the stock market, unfortunately.

Moderator

Well, thank you so much, Nikolaj.

Nikolaj Sørensen
President and CEO, Orexo

Thank you.